Exhibit 99.2
CONFIDENTIAL
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. […***…] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION
January 11, 2019
[…***…]1
Medicines Research Centre
Gunnels Wood Road
Stevenage, Hertfordshire SG1 2NY
United Kingdom
VIA EMAIL
Attention:[…***…]2
RE:EXTENSION OF RESEARCH COLLABORATION TERM
Dear […***…]3,
Reference is hereby made to the Collaboration and Research License Agreement between GlaxoSmithKline Intellectual Property Development Limited (“GSK”) and Zymeworks Inc. (“Zymeworks”) dated December 1, 2015 (the “Agreement”). Unless otherwise defined herein, all capitalized terms have the meanings ascribed to them in the Agreement.
This letter sets out GSK and Zymeworks’ agreement to extend conclusion of the Research Collaboration Term under the Agreement until the earlier of (a) […***…] or (b) the date on which the […***…], unless earlier terminated in accordance with Section 10.2, 10.3 or 10.4 of the Agreement. Such extension of the Research Collaboration Term shall take effect as of November 30, 2018.4
If the foregoing accurately reflects your understanding, please indicate your agreement in the space provided below and return a fully executed copy of this letter to Zymeworks.
Sincerely,
Zymeworks Inc.
By: | /s/ Neil Klompas | |
Neil A. Klompas, | ||
Chief Financial Officer |
Acknowledged and agreed:
GlaxoSmithKline Intellectual Property Development Limited
By: | /s/ John Sadler |
1 | Personal Information – Contact Information. |
2 | Personal Information – Contact Information. |
3 | Personal Information – Contact Information. |
4 | Competitive Information – Commercially Sensitive Terms. |
CONFIDENTIAL
By: | /s/Paul Williamson |
Authorized Signatory
For and on behalf of
Edinburgh Pharmaceutical Industries Limited
Corporate Director
cc: […***…]5
5 | Personal Information – Contact Information. |